BTEE.L vs. DOCT.L
Compare and contrast key facts about iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) and L&G Healthcare Breakthrough UCITS ETF (DOCT.L).
BTEE.L and DOCT.L are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BTEE.L is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology TR USD. It was launched on Mar 5, 2018. DOCT.L is a passively managed fund by Legal & General that tracks the performance of the MSCI World/Health Care NR USD. It was launched on Jun 26, 2019. Both BTEE.L and DOCT.L are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
BTEE.L vs. DOCT.L - Performance Comparison
Loading graphics...
BTEE.L vs. DOCT.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 3.29% | 32.82% | -1.69% | 5.84% | -11.88% | -0.57% | 27.55% | 9.75% |
DOCT.L L&G Healthcare Breakthrough UCITS ETF | -6.39% | 24.88% | 1.98% | -1.20% | -33.86% | 0.19% | 66.94% | 5.40% |
Returns By Period
In the year-to-date period, BTEE.L achieves a 3.29% return, which is significantly higher than DOCT.L's -6.39% return.
BTEE.L
- 1D
- 2.25%
- 1M
- -1.36%
- YTD
- 3.29%
- 6M
- 17.25%
- 1Y
- 39.34%
- 3Y*
- 13.16%
- 5Y*
- 4.62%
- 10Y*
- —
DOCT.L
- 1D
- 3.54%
- 1M
- -4.85%
- YTD
- -6.39%
- 6M
- 7.90%
- 1Y
- 24.06%
- 3Y*
- 4.40%
- 5Y*
- -5.16%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BTEE.L vs. DOCT.L - Expense Ratio Comparison
BTEE.L has a 0.35% expense ratio, which is lower than DOCT.L's 0.49% expense ratio.
Return for Risk
BTEE.L vs. DOCT.L — Risk / Return Rank
BTEE.L
DOCT.L
BTEE.L vs. DOCT.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) and L&G Healthcare Breakthrough UCITS ETF (DOCT.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BTEE.L | DOCT.L | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.77 | 1.09 | +0.67 |
Sortino ratioReturn per unit of downside risk | 2.38 | 1.64 | +0.74 |
Omega ratioGain probability vs. loss probability | 1.31 | 1.20 | +0.11 |
Calmar ratioReturn relative to maximum drawdown | 3.20 | 1.44 | +1.76 |
Martin ratioReturn relative to average drawdown | 14.39 | 4.78 | +9.62 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BTEE.L | DOCT.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.77 | 1.09 | +0.67 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | -0.22 | +0.43 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.30 | 0.19 | +0.11 |
Correlation
The correlation between BTEE.L and DOCT.L is 0.80, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
BTEE.L vs. DOCT.L - Dividend Comparison
BTEE.L's dividend yield for the trailing twelve months is around 0.36%, while DOCT.L has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.36% | 0.37% | 0.46% | 0.39% | 0.44% | 0.25% | 0.17% | 0.14% | 0.07% |
DOCT.L L&G Healthcare Breakthrough UCITS ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
BTEE.L vs. DOCT.L - Drawdown Comparison
The maximum BTEE.L drawdown since its inception was -38.29%, smaller than the maximum DOCT.L drawdown of -57.55%. Use the drawdown chart below to compare losses from any high point for BTEE.L and DOCT.L.
Loading graphics...
Drawdown Indicators
| BTEE.L | DOCT.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.29% | -57.55% | +19.26% |
Max Drawdown (1Y)Largest decline over 1 year | -14.02% | -17.02% | +3.00% |
Max Drawdown (5Y)Largest decline over 5 years | -38.29% | -55.82% | +17.53% |
Current DrawdownCurrent decline from peak | -2.70% | -34.50% | +31.80% |
Average DrawdownAverage peak-to-trough decline | -13.78% | -28.94% | +15.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.81% | 5.12% | -2.31% |
Volatility
BTEE.L vs. DOCT.L - Volatility Comparison
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) and L&G Healthcare Breakthrough UCITS ETF (DOCT.L) have volatilities of 7.46% and 7.64%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BTEE.L | DOCT.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.46% | 7.64% | -0.18% |
Volatility (6M)Calculated over the trailing 6-month period | 14.21% | 14.62% | -0.41% |
Volatility (1Y)Calculated over the trailing 1-year period | 22.17% | 21.92% | +0.25% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.18% | 23.89% | -2.71% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.50% | 24.72% | -2.22% |